Virtual crossmatching improves quality of life for kidney transplant patients

31 January 2020

Virtual antibody crossmatching is a safe and efficient way of selecting kidney transplant recipients. Credit: American College of Surgeons

Virtual antibody crossmatching is a safe and efficient way of selecting kidney transplant recipients. Since 1969, physical crossmatching has been used to determine if the immune systems of an organ donor and an intended recipient were compatible. Blood from donor and recipient are mixed in a test tube. If a match is incompatible, recipient blood cells attack and destroy donor cells.

However, virtual crossmatching applies the recipient's serum to microbeads that detect signals from the donor's antibodies using a specialized device to find antibodies that may react. The process does not reveal an actual reaction between donor and recipient cells. Rather, it forecasts whether such a reaction would occur.

A physical crossmatch is highly sensitive, but it eats up valuable time. Donor lymph nodes are shipped to the transplant center, cells are mixed with serum from the potential recipient, and surgeons, recipient, and the transplant center then must wait six hours to learn whether there is an antibody reaction before scheduling the operation.

Because of the concern about potential immune system incompatibility, transplant centers typically call in three possible recipients for every donated organ. "We ask three patients who are next on the transplantation list to come into the hospital just in case there are problems with incompatibility. Think about the time, effort, and stress that puts on a patient. It's not uncommon for a patient to be called in two, three, or four times before they actually go forward with transplantation," said David J. Taber, PharmD, a study coauthor and an associate professor of surgery in the division of transplant surgery at MUSC.

The delay prolongs the time a donated organ is kept on ice, called cold ischemia time (CIT). "You want to minimize the amount of time an organ is on ice because the longer it is outside the body, the lower quality it becomes. After prolonged CIT, there is the chance the organ will not function right away, called delayed graft function (DGF), which leads to poor outcomes in the long run," said Vinayak S. Rohan, MD, FACS, lead author of the study and an assistant professor of surgery in the division of...
transplant surgery at MUSC.

Delays are particularly problematic since the Kidney Allocation System was revised in 2014 and now allows transplantations to patients who are highly sensitized.\(^3\) "Previously, donor organs were obtained locally, so transplant centers could afford to wait six hours for the physical crossmatch results. Now, in South Carolina, we are getting organs from California. Shipping them takes long enough. If you cannot predict what is going to happen for six more hours, you may not be able to give the organ to the intended recipient and do a disservice to the purpose of the allocation system," said Dr. Rohan.

The study is a before-and-after comparison of patient outcomes two years after the transplant surgery team implemented virtual crossmatching. Of 825 patients who received a kidney transplant between 2014 and 2018, 505 underwent surgery before—and 227 after—virtual crossmatching was instituted.

Standard measures of clinical quality were the same in both groups. The incidence of delayed graft function was 19 percent before and 17 percent after implementation; graft failure within a year was 4 percent before and 3 percent after; mortality within a year was 2 percent before and 1 percent after.

CIT for long-distance donor organs decreased by 2.4 hours, and delayed graft function declined by 26 percent. Importantly, despite a highly sensitized population, there were no hyperacute rejections. "Hyperacute rejection is an extremely rare but catastrophic event when an organ rejects while the surgeon is operating. With sizable segments of patients who were already highly sensitized, there were similar rates of graft survival, patient survival, and kidney graft survival, confirming at a patient-outcomes level that we can employ virtual crossmatching without inducing any potential harm or risk to the patient," Dr. Taber said.

"Because we don't need to do physical crossmatching for the majority of patients, we also can improve surgeons' quality of life by being able to schedule the operation even before an organ arrives," Dr. Rohan said.

"This technique also reduces the time and money spent on having backup patients traveling to and waiting in the hospital. Emotionally, this approach helps patients a lot," Dr. Taber said.

Dr. Rohan's coauthors are Nicole Pilch; PharmD, Omar Moussa; Ph.D., Satish N. Nadig, MD, FACS; Derek Dubay, MD, FACS; and Prabhakar K. Baliga, MD, FACS.


This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.